Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Phase of Trial: Phase III
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Biotin (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms SPI2
- Sponsors MedDay Pharmaceuticals
- 15 Mar 2017 Planned number of patients changed to 754.
- 20 Feb 2017 Planned number of patients changed from 300 to 600.
- 20 Feb 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Sep 2018.